Q BioMed Inc. (QBIO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 8.13 Million USD | 48.01% |
| 2021 | 5.49 Million USD | 223.42% |
| 2020 | 1.69 Million USD | -70.12% |
| 2019 | 5.68 Million USD | 72.15% |
| 2018 | 3.3 Million USD | 601.14% |
| 2017 | 471.03 Thousand USD | -86.59% |
| 2016 | 3.51 Million USD | 806.72% |
| 2015 | 387.31 Thousand USD | 32203.0% |
| 2014 | 1199.00 USD | 139.8% |
| 2013 | 500.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | 9.9 Million USD | 21.8% |
| 2023 Q2 | - USD | -100.0% |
| 2022 Q2 | 7.56 Million USD | 18.73% |
| 2022 Q4 | 8.13 Million USD | 5.18% |
| 2022 Q3 | 7.73 Million USD | 2.26% |
| 2022 FY | 8.13 Million USD | 48.01% |
| 2022 Q1 | 6.36 Million USD | 15.89% |
| 2021 Q2 | 2.97 Million USD | 12.4% |
| 2021 FY | 5.49 Million USD | 223.42% |
| 2021 Q4 | 5.49 Million USD | 52.72% |
| 2021 Q3 | 3.59 Million USD | 20.86% |
| 2021 Q1 | 2.64 Million USD | 55.9% |
| 2020 Q1 | 6.46 Million USD | 13.72% |
| 2020 Q4 | 1.69 Million USD | -3.39% |
| 2020 FY | 1.69 Million USD | -70.12% |
| 2020 Q2 | 1.51 Million USD | -76.55% |
| 2020 Q3 | 1.75 Million USD | 15.99% |
| 2019 Q4 | 5.68 Million USD | -16.82% |
| 2019 Q3 | 6.83 Million USD | 35.55% |
| 2019 Q2 | 5.04 Million USD | 32.49% |
| 2019 FY | 5.68 Million USD | 72.15% |
| 2019 Q1 | 3.8 Million USD | 15.25% |
| 2018 Q1 | 570.31 Thousand USD | 21.08% |
| 2018 FY | 3.3 Million USD | 601.14% |
| 2018 Q4 | 3.3 Million USD | 367.1% |
| 2018 Q3 | 707.05 Thousand USD | 60.59% |
| 2018 Q2 | 440.29 Thousand USD | -22.8% |
| 2017 FY | 471.03 Thousand USD | -86.59% |
| 2017 Q4 | 471.03 Thousand USD | -81.11% |
| 2017 Q3 | 2.49 Million USD | -25.15% |
| 2017 Q2 | 3.33 Million USD | 51.07% |
| 2017 Q1 | 2.2 Million USD | -37.19% |
| 2016 FY | 3.51 Million USD | 806.72% |
| 2016 Q1 | 998.13 Thousand USD | 157.71% |
| 2016 Q3 | 1.75 Million USD | 51.92% |
| 2016 Q2 | 1.15 Million USD | 15.71% |
| 2016 Q4 | 3.51 Million USD | 100.15% |
| 2015 FY | 387.31 Thousand USD | 32203.0% |
| 2015 Q1 | 99.00 USD | -91.74% |
| 2015 Q4 | 387.31 Thousand USD | 22913.25% |
| 2015 Q2 | 164.00 USD | 65.66% |
| 2015 Q3 | 1683.00 USD | 926.22% |
| 2014 Q4 | 1199.00 USD | 139.8% |
| 2014 Q1 | 590.00 USD | 0.0% |
| 2014 Q3 | 500.00 USD | 0.0% |
| 2014 Q2 | 500.00 USD | -15.25% |
| 2014 FY | 1199.00 USD | 139.8% |
| 2013 FY | 500.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -29546.553% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 14.082% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 88.778% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -905.564% |
| Rebus Holdings, Inc. | 5.24 Million USD | -55.15% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 86.219% |
| Qrons Inc. | 1.48 Million USD | -446.307% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -563.257% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 89.145% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -18096.123% |
| Skye Bioscience, Inc. | 14.07 Million USD | 42.206% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 84.743% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 15.123% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1829.212% |
| SQZ Biotechnologies Company | 50.03 Million USD | 83.747% |
| Intellipharmaceutics International Inc. | 12 Million USD | 32.275% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -111.167% |
| Mesoblast Limited | 188.44 Million USD | 95.684% |
| Marizyme, Inc. | 26.67 Million USD | 69.512% |
| Genus plc | 485 Million USD | 98.323% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -39.2% |
| Pharming Group N.V. | 244.07 Million USD | 96.668% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -304.598% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -223.207% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -114.025% |
| ContraFect Corporation | 32.53 Million USD | 74.999% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -310.483% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -112.479% |
| IMV Inc. | 37.93 Million USD | 78.56% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 30.949% |
| MultiCell Technologies, Inc. | 1617.67 USD | -502656.372% |
| ONE Bio Corp. | 27.49 Million USD | 70.421% |
| Accustem Sciences Inc. | 1.07 Million USD | -653.581% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 89.495% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -284.524% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 90.194% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -58.043% |
| Biomind Labs Inc. | 1.49 Million USD | -442.698% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 93.15% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 10.056% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 55.807% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -467.206% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -5623.593% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -3943.905% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -41.545% |
| GB Sciences, Inc. | 5.41 Million USD | -50.122% |
| Alpha Cognition Inc. | 7.16 Million USD | -13.513% |
| HST Global, Inc. | 593.59 Thousand USD | -1270.12% |
| CSL Limited | 18.62 Billion USD | 99.956% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -545.885% |
| Halberd Corporation | 728.71 Thousand USD | -1016.06% |
| Enzolytics Inc. | 365.26 Million USD | 97.773% |
| Agentix Corp. | 2.51 Million USD | -223.95% |
| Resverlogix Corp. | 67.39 Million USD | 87.933% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -869.671% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.172% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -374.501% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 67.134% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 31.674% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -121.898% |
| AVAX Technologies, Inc. | 3.99 Million USD | -103.642% |
| Zenith Capital Corp. | 27.56 Thousand USD | -29400.305% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.387% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -3307.837% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -117.79% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1094.555% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -199.927% |
| Kadimastem Ltd | 3.5 Million USD | -132.047% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -12051.592% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 83.82% |
| BioStem Technologies, Inc. | 15.9 Million USD | 48.864% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1650.152% |
| LadRx Corporation | 2.2 Million USD | -269.59% |
| Cell Source, Inc. | 15.8 Million USD | 48.548% |
| Regen BioPharma, Inc. | 5.45 Million USD | -49.02% |
| Regen BioPharma, Inc. | 5.45 Million USD | -49.02% |
| NovAccess Global Inc. | 7.86 Million USD | -3.463% |
| Affymax, Inc. | 8.87 Million USD | 8.32% |
| Itoco Inc. | 1.65 Million USD | -391.966% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -296.426% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -34.451% |
| Mobile Lads Corp. | 1.31 Million USD | -519.182% |
| CytoDyn Inc. | 127.89 Million USD | 93.641% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -19357.257% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -419.22% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 26.367% |
| SYBLEU INC | 681.41 Thousand USD | -1093.54% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -33.285% |
| International Stem Cell Corporation | 5.27 Million USD | -54.121% |
| Bioxytran, Inc. | 3.24 Million USD | -150.283% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1199.588% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -76.147% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 80.162% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 63.472% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -301.55% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -48.465% |
| Neutra Corp. | 973.52 Thousand USD | -735.408% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 71.97% |
| PureTech Health plc | 125.58 Million USD | 93.524% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -116.467% |
| IXICO plc | 1.9 Million USD | -327.984% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 60.383% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 92.129% |
| CSL Limited | 18.62 Billion USD | 99.956% |
| Cellectis S.A. | 249.36 Million USD | 96.739% |